Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genzyme

- PMLiVE

TG signs $645m deal with Neuraxpharm to support international launch of MS antibody

Briumvi has already been approved in the US and EU for adults with relapsing forms of MS

- PMLiVE

Scleroderma Research Foundation launches clinical trial platform to advance treatments

The initiative will initially focus on interstitial lung disease secondary to scleroderma but will be expanded to address other manifestations of the disease

- PMLiVE

UK experts and politicians meet to discuss challenges faced by progressive MS patients

Primary-progressive MS accounts for approximately 10-15% of multiple sclerosis cases

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody receives FDA approval for use in infants

Beyfortus is the now first preventive option approved in the US to protect a broad infant population

- PMLiVE

Sanofi and Scribe announce in vivo genetic therapy partnership worth over $1.2bn

The agreement expands the companies’ existing collaboration focused on ex vivo editing

- PMLiVE

Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial

The therapy is already approved for certain MS patients as a twice-yearly intravenous infusion

- PMLiVE

Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial

The inflammatory skin disease affects an estimated 16.5 million adults in the US

- PMLiVE

Sanofi and Sobi’s haemophilia A treatment shows effective bleed protection in children

Current factor VIII therapies usually require patients to receive treatment multiple times a week

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

Sanofi’s frexalimab shows promise in relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links